Technical Data
A0868-36F
Adeno-Associated Virus 2, VP1, VP2 (AAV2)
Description:
Applications:
Suitable for use in Immunofluorescence microscopy, Immunohistochemistry, Immunoprecipitation, Immunoblot.

Recommended Dilution:
Immunohistochemistry: 1:10; Incubation Time 1 hr at room temperature.

Storage and Stability:
Lyophilized powder may be stored at 4C for short-term only. Reconstitute to nominal volume by adding sterile 40-50% glycerol and store at -20C. Reconstituted product is stable for 12 months at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
TypeIsotypeCloneGrade
MabIgG15F149Affinity Purified
SizeStorageShippingSourceHost
50ug-20CBlue IceMouse
Concentration:
~0.05mg/ml
Immunogen:
Adeno-associated virus capsid proteins and virus particles.
Purity:
Purified by Protein A affinity chromatography.
Form
Supplied as a lyophilized powder in PBS, 0.5% BSA, 0.09% sodium azide. Reconstitute to 1ml final volume.
Specificity:
Recognized AAV-2, found in human and monkey. Weak crossreaction with serotypes 1, 3, and 6. Reacts with VP 1 and VP 2 of adeno-associated virus which are highly enriched in the nucleus. Epitope mapping experiments identified aa169 to aa184 of VP2 and (with reduced intensity) aa123 to aa136 of VP1 capsid proteins as the specific binding region.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
Wistuba A.,Weger S., Kern A., and Kleinschmidt J. (1995) Intermediates of adeno-associated virus type 2 assembly: Identification of soluble complexes containing Rep and Cap proteins. J. Virol. 69, 5311-5319.
Wistuba A., Kern A., Weger S., Grimm D., and Kleinschmidt J. (1997) Subcellular compartmentalization of adeno-associated virus type 2 assembly. J. Virol. 71, 1341-1352. Wobus C.A., Hgle-Drr B., Girod A., Petersen G., Hallek M. and Kleinschmidt J.A. (2000) Monoclonal antibodies against the adenoassociated virus type 2 (AAV-2) capsid: Epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection. J. Virology 74, 9281-9293.